ATHE
Alterity Therapeutics LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$68.13M
P/E Ratio
—
EPS
$-0.58
Beta
-0.07
52W High
$7.00
52W Low
$2.52
50-Day MA
$3.42
200-Day MA
$4.02
Dividend Yield
—
Profit Margin
-219.90%
Forward P/E
—
PEG Ratio
—
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Fundamentals
| Revenue (TTM) | $6.64M |
| Gross Profit (TTM) | $6.47M |
| EBITDA | $-17.55M |
| Operating Margin | -372.60% |
| Return on Equity | -47.00% |
| Return on Assets | -32.50% |
| Revenue/Share (TTM) | $0.60 |
| Book Value | $0.00 |
| Price-to-Book | 1.72 |
| Price-to-Sales (TTM) | 10.27 |
| EV/Revenue | 113.99 |
| EV/EBITDA | 0.76 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 74.60% |
| Shares Outstanding | $18.13M |
| Float | $8.31B |
| % Insiders | 0.00% |
| % Institutions | 1.80% |
Data last updated: 4/7/2026